Yet Another Bad Day For PBMs On Capitol Hill
Democrats and Republicans in the US Congress are not getting along on most topics these days. But when it comes to criticizing the pharmacy benefit management sector, they see eye-to-eye.
You may also be interested in...
The brand drug industry’s success in tackling COVID-19 followed by swift political loss with the Inflation Reduction Act is in part due to the public’s continued knowledge gaps about the medical innovation ecosystem, outgoing PhRMA VP Jenny Bryant tells Pink Sheet in an interview.
New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.
There was lots of criticism of pharmacy benefit managers (and a fair amount aimed at pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.